Sergey Ryazanov

Anle138b reduces mHTT aggregates and improves disease phenotypes in HD cell and mouse models.

This paper shows that anle138b binds to a cavity in lipidic Aβ fibrils and reduces fibril formation by 75%, suggesting a potential therapeutic mechanism for Alzheimer's disease.

This study identifies two binding sites of the PET tracer MODAG-005 on lipidic α-synuclein fibrils, with the cavity site being more stable and selectively occupied under certain conditions.

This study shows that anle138b reduces hyperglycemia and improves pancreatic islet function in hIAPP Ob/Ob mice by mitigating hIAPP toxicity.

The paper evaluates pharmacological modulators of α-synuclein and tau aggregation and internalization, identifying compounds that reduce their aggregation and spread.

This study develops a new Parkinson's disease mouse model showing that reducing α-synuclein aggregates rescues dopamine neuron dysfunction and death.